New Study Points To Systemic Inflammation As An Independent Predictor of Low Bone Mineral Density (Osteopenia) In Stable COPD Patients

Share Article

A recent study has concluded that systemic inflammation (dysregulated inflammation) is an indicator for Osteopenia (low bone mineral density) in individuals with COPD. Nutri-Med Logic Corp states that categorizing systemic inflammation, as a risk factor in Osteopenia, should not be limited to only individuals with COPD, rather to all adults.

Nutri-Med Logic Corp: A recent study published in Endocrine Magazine is suggesting a link between Osteopenia (low bone mineral density) and those with a stable COPD. In general, systemic inflammation has been implicated in those with COPD, stable or unstable. However, systemic inflammation is not limited to only those with COPD but a dysregulated inflammation (systemic inflammation) poses a risk to all adults.

Bone remodeling (removing the old and making new bone tissues) is realized through two distinct cell lines: Osteoblasts (making new bone tissues) and Osteoclasts (removing the old tissue)
Osteoblasts, upon terminating their task signal Osteoclasts. This signal is an inflammatory signal (IL-6).

Accordingly, inflammation, an immune mechanism, is a pathway to bone remodeling, which is a normal and biological process. However, when the body loses its homeostasis or, in another word, the inflammation becomes dysregulated and sustained, then the activities of Osteoclasts increases, without a need, and thus more bone tissues are unnecessarily removed resulting in bone density reduction, initially producing Osteopenia and, if not controlled, it might progress to Osteoporosis.

Inflammation, an immune mechanism, starts locally via the cellular membranes through a group of short-lived local hormones (Prostaglandins-2), which are the derivatives of the fatty acids of Omega-6.

The local inflammation is a clinical (acute) inflammation and, in most cases, it subsides. However, when inflammation does not subside, then inflammatory signals circulate the entire body, and if sustained without resolution, the inflammation becomes systemic (general).
The primary mechanism for the resolution of the inflammation also starts from the cellular membrane and through another group of short-lived local hormones (Prostaglandins-3) but these are the derivatives of the fatty acids of Omega-3.

The membrane ratio of Omeg-3/Omega-6 contributes to the intensity and the duration of inflammation. Both Omega-3 and Omega-6 are only obtained from diet.

Omega-6 is mainly found red meat and seeds, Omeg-3 in cold-water fishes and green leafy vegetables. Diet lacking Omega-3 tilts the balance to the pro-inflammatory Omega-6, since the cellular membranes must fulfill their membrane phospholipid polyunsaturated fatty acids requirement with either Omega 3 or Omega-6.

One of the natural ways to moderate inflammation, as it relates to Omega-6, is attained through supplementation of Omega-3, a competitor of Omega-6.

Lack of anti-inflammatory nutrients, such as Omega-3, contributes to an increased level and concentration of Omega-6 or, in another word, to the intensity and the duration of inflammation. When inflammation lingers around, then it becomes systemic.

Systemic inflammation also incorporates IL-6, the signal that activates the bone removing cells. Prolonged systemic inflammation contributes to the sustained but unnecessary activation of bone removing cells.

A more vivid example of inflammation and Osteoporosis is the menopausal Osteoporosis, which is mainly due to the loss of the estrogen, an anti-inflammatory hormone.

Omega-3 is an anti-inflammatory nutrient. Two important Omega-3 fatty acids are:
DHA, the precursor to Resolvins D, which resolves inflammation in brain and nervous system.
EPA, the precursor to Resolvin E, which resolves inflammation in cardiovascular system.

In conclusion, Nutri-Med Logic Corp agrees with this recent study but adds that systemic inflammation is not an Osteopenia risk limited to those suffering from COPD, rather to all adults.
Nutri-Med Logic Corp. is a producer of dietary supplements, including a Natural, Balanced, Deodorized and Concentrated Omega-3, which is also a Pharmaceutical Grade Omega-3.

Nutri-Med Logic Corp. is also a producer of PolyEnylPhosphatidylCholine (PPC 425mg), an extract of soy and the recommended dietarty supplement for those with Fatty Liver and Alcoholic Liver Disease, in Europe for about 50 years; producer of a Pharmaceutical Grade R-Alpha Lipioic Acid, the dietary supplement of choice for the Diabetics, in Germany for more than 40 years.

Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.

It must be noted that the studies, sources or statements above have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the dietary supplements, stated herein, nor equate their supplementation to prevention, treatment or cure.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

H.R. Zadeh
Visit website